We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » The Medicines Co.’s Post-Angioplasty Drug Kengreal Gets FDA Green Light
The Medicines Co.’s Post-Angioplasty Drug Kengreal Gets FDA Green Light
More than a year after being rejected by the FDA, The Medicines Company’s intravenous antiplatelet drug Kengreal has received the go-ahead as a post-angioplasty anticlotting agent.